Related Experiment Videos
[Rationale of preoperative chemotherapy of osteosarcoma]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 1, 1987
Summary
Preoperative chemotherapy significantly improves the 5-year survival rate for osteosarcoma patients. Tumor response to chemotherapy correlates with decreased serum alkaline phosphatase levels, aiding treatment assessment.
Area of Science:
- Orthopedic Oncology
- Surgical Oncology
- Medical Oncology
Context:
- Osteosarcoma, a primary bone cancer, often presents with microscopic metastases.
- Preoperative chemotherapy aims to eradicate micrometastases, define surgical margins, and enable limb-salvage procedures.
Purpose:
- To analyze the impact of preoperative chemotherapy on the 5-year survival rate in osteosarcoma patients.
- To assess the efficacy of systemic chemotherapy in improving survival outcomes.
- To evaluate the correlation between tumor response markers and chemotherapy effectiveness.
Summary:
- This study analyzed 49 patients with non-metastatic osteosarcoma of the extremities treated with radical surgery.
- The systemic chemotherapy group (20 cases) demonstrated a significantly higher 5-year survival rate (56.7%) compared to a historical retrospective group (13.8%).
- A strong correlation was observed between tumor necrotic ratio and decreased serum alkaline phosphatase levels in assessing chemotherapy response.
Impact:
- Preoperative chemotherapy offers a significant survival benefit for osteosarcoma patients.
- Serum alkaline phosphatase levels can serve as a predictive marker for tumor response to chemotherapy.
- Findings support the integration of preoperative chemotherapy in osteosarcoma treatment protocols.